Loading
FibroBiologics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Khoja Hamid, was filed 05 Mar 2026.
Insider Decl.
13
Thresholds
n/a
Buy Volume
€149,971
10 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySalePete O'Heeron3 buys
Hamid Khoja2 buys
Ruben A. Garcia2 buys
Jason Davis1 buy
Since the insiders bought
- -89.4%Entry US$8.70 · Close 20 Oct 2026 US$0.92
- -89.0%Entry US$8.38 · Close 20 Oct 2026 US$0.92
- -87.8%Entry US$7.52 · Close 20 Oct 2026 US$0.92
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.92
Analyst consensus
2 analysts2.00/5
US$6.00Target US$12.50(+1259%)US$19.00
Income statement
EBITDA-US$17.6M
Net income-US$18.6M0.0% margin
Valuation
PER (forward)-0.3x
P/Book1.2x
Beta1.74
Balance sheet & cash
Market capUS$6.5M
Total debtUS$2.4M
Free Cash Flow-US$16.7M
Debt / Equity32%
Profitability & ownership
ROE-660.1%
ROA-95.8%
% insiders13.7%
% institutions15.3%
Last declaration on 15 September 2026
Declarations13 total
298,508 shares@ US$1.6757.08% mcap91.2% of flowCommon StockSEC:0001493152-26-042794:0
30,000 shares@ US$0.382.1% of flowCommon StockSEC:0001493152-26-008933:0
Canonical exit: 2 Jun 2026 (T+90)
18,200 shares@ US$0.405120.0% of flowCommon StockSEC:0001493152-26-008903:1
Canonical exit: 1 Jun 2026 (T+90)
15,872 shares@ US$0.378416.4% of flowCommon StockSEC:0001493152-26-008903:2
Canonical exit: 2 Jun 2026 (T+90)
17,428 shares@ US$0.35326.0% of flowCommon StockSEC:0001493152-26-008903:0
Canonical exit: 31 May 2026 (T+90)
70,000 shares@ US$0.4139100.0% of flowCommon StockSEC:0001493152-26-008646:0
Canonical exit: 31 May 2026 (T+90)
40,000 shares@ US$0.326421.4% of flowCommon StockSEC:0001493152-26-008469:0
Canonical exit: 28 May 2026 (T+90)
140,000 shares@ US$0.3478.6% of flowCommon StockSEC:0001493152-25-027363:0
Canonical exit: 11 Mar 2026 (T+90)
20,000 shares@ US$0.843.1% of flowCommon StockSEC:0001641172-25-012539:0
Canonical exit: 25 Aug 2025 (T+90)
100,000 shares0Common StockSEC:0001493152-24-049341:0
50,000 shares0Common StockSEC:0001493152-24-048916:0
10,000 shares@ US$1.903.7% of flowCommon StockSEC:0001493152-24-031438:0
Canonical exit: 10 Nov 2024 (T+90)
8,500 shares@ US$1.91474.0% of flowCommon StockSEC:0001493152-24-031439:0
Canonical exit: 10 Nov 2024 (T+90)
13 of 13 declarations
About FibroBiologics, Inc.
FibroBiologics, Inc. is a US health company listed on Nasdaq, with a known market capitalisation of USD 6,514,457, and its four filers hold 13.7% of the capital. The record holds 13 filings published from August 12, 2024 to September 15, 2026, and it is one of buyers: 10 purchases worth EUR 149,971, median EUR 12,940, with no sale at all.
The largest purchase, EUR 40,679, is by Ruben A. Garcia, General Counsel, on December 11, 2025. Jason Davis, Chief Financial Officer, bought EUR 24,638 on March 2, 2026, and Hamid Khoja, Chief Scientific Officer, EUR 17,373 on August 12, 2024. From February 27 to March 4, 2026, the four insiders bought EUR 62,224 in all. Across the full history, 5 purchase filings are classed as clustered. Pete O'Heeron, CEO, is the top filer with 6 filings, 4 of them purchases; Hamid Khoja files 4, 3 of them purchases.
Read moreShow less
The record also holds one grant and 2 filings of another nature. Activity grows: 4 filings in 2024, 2 in 2025 and 7 in 2026. Over the last twelve months there are 8 filings, 7 of them purchases. Filings are published a median of one day after the trade.
